Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
grade B 81.37 2.33% 1.85
UTHR closed up 2.33 percent on Friday, August 16, 2019, on 59 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical UTHR trend table...

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
20 DMA Support Bullish 2.33%
50 DMA Support Bullish 2.33%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.33%
Multiple of Ten Bearish Other 2.33%
20 DMA Support Bullish 2.58%
50 DMA Support Bullish 2.58%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.58%
Doji - Bullish? Reversal 2.58%
Multiple of Ten Bearish Other 2.58%

Older signals for UTHR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Chemistry Biotechnology Chemical Compounds Infectious Diseases Organic Compounds Alcohols Pulmonary Arterial Hypertension Hepatitis C Neuroblastoma Pulmonary Hypertension Treprostinil Cac All Share Index Chronic And Life Threatening Conditions Oral Therapy Prostaglandins
Is UTHR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 129.59
52 Week Low 74.31
Average Volume 605,892
200-Day Moving Average 101.9679
50-Day Moving Average 78.9088
20-Day Moving Average 79.3245
10-Day Moving Average 80.221
Average True Range 2.547
ADX 19.58
+DI 25.3164
-DI 15.8729
Chandelier Exit (Long, 3 ATRs ) 77.669
Chandelier Exit (Short, 3 ATRs ) 81.951
Upper Bollinger Band 83.9332
Lower Bollinger Band 74.7158
Percent B (%b) 0.72
BandWidth 11.619865
MACD Line 0.4136
MACD Signal Line 0.2375
MACD Histogram 0.1761
Fundamentals Value
Market Cap 3.54 Billion
Num Shares 43.5 Million
EPS 8.62
Price-to-Earnings (P/E) Ratio 9.44
Price-to-Sales 3.17
Price-to-Book 2.91
PEG Ratio -0.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.96
Resistance 3 (R3) 84.71 83.27 84.36
Resistance 2 (R2) 83.27 82.36 83.39 84.16
Resistance 1 (R1) 82.32 81.79 82.80 82.57 83.96
Pivot Point 80.88 80.88 81.12 81.00 80.88
Support 1 (S1) 79.93 79.97 80.41 80.18 78.78
Support 2 (S2) 78.49 79.40 78.61 78.58
Support 3 (S3) 77.54 78.49 78.38
Support 4 (S4) 77.79